Forte Biosciences, Inc., a Dallas-based biopharmaceutical company with nine employees, specializes in dermatology products and services and went public on April 13, 2017. The company is developing FB-102, a therapeutic molecule aimed at treating autoimmune conditions like GvHD, vitiligo, and alopecia areata.
Forte Biosciences (FBRX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Forte Biosciences's actual EPS was -$6.75, missing the estimate of -$4.25 per share, resulting in a -58.82% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
